Open AccessGenetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample
Author(s) -
Rothwell Dominic G.,
Smith Nigel,
Morris Daniel,
Leong Hui Sun,
Li Yaoyong,
Hollebecque Antoine,
Ayub Mahmood,
Carter Louise,
Antonello Jenny,
Franklin Lynsey,
Miller Crispin,
Blackhall Fiona,
Dive Caroline,
Brady Ged
Publication year - 2016
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1016/j.molonc.2015.11.006
Subject(s) - circulating tumor dna , circulating tumor cell , whole blood , blood cancer , genotype , limiting , dna , computational biology , biology , liquid biopsy , cancer , medicine , oncology , cancer research , genetics , gene , metastasis , mechanical engineering , engineering
Molecular information obtained from cancer patients' blood is an emerging and powerful research tool with immense potential as a companion diagnostic for patient stratification and monitoring. Blood, which can be sampled routinely, provides a means of inferring the current genetic status of patients' tumours via analysis of circulating tumour cells (CTCs) or circulating tumour DNA (ctDNA). However, accurate assessment of both CTCs and ctDNA requires all blood cells to be maintained intact until samples are processed. This dictates for ctDNA analysis EDTA blood samples must be processed with 4 h of draw, severely limiting the use of ctDNA in multi‐site trials. Here we describe a blood collection protocol that is amenable for analysis of both CTCs and ctDNA up to four days after blood collection. We demonstrate that yields of circulating free DNA (cfDNA) obtained from whole blood CellSave samples are equivalent to those obtained from conventional EDTA plasma processed within 4 h of blood draw. Targeted and genome‐wide NGS revealed comparable DNA quality and resultant sequence information from cfDNA within CellSave and EDTA samples. We also demonstrate that CTCs and ctDNA can be isolated from the same patient blood sample, and give the same patterns of CNA enabling direct analysis of the genetic status of patients' tumours. In summary, our results demonstrate the utility of a simple approach that enabling robust molecular analysis of CTCs and cfDNA for genotype‐directed therapies in multi‐site clinical trials and represent a significant methodological improvement for clinical benefit.